RxDoctor Payments Data

Silvana Matte, MD

Family Medicine · East China, MINPI 1164657557

Payments from drug & device makers

$3,560in general payments, 2019–2025

Across 183 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$424
  • Novo Nordisk$385
  • Abbott$233
  • AbbVie$228
  • GSK$202
  • Dexcom, Inc.$193
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,560 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$73,573
Medicare patients
165
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$45,824
OzempicSemaglutide17$33,466
JardianceEmpagliflozin25$28,624
RybelsusSemaglutide17$27,121
TrulicityDulaglutide13$11,654
MyrbetriqMirabegron14$9,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,704
PaxlovidNirmatrelvir/Ritonavir16$5,441
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$5,365
Atorvastatin Calcium300$3,861
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,630
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,520
Novolog FlexpenInsulin Aspart19$3,361
Levothyroxine Sodium151$1,750
Losartan Potassium122$1,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$385$60,58834 claims
PfizerEliquis, Paxlovid$110$51,26471 claims
Boehringer IngelheimJardiance$31$28,62425 claims
Lilly USA, LLCTrulicity$125$11,65413 claims
GSKTrelegy Ellipta$202$9,70415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in East China

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →